公开(公告)号：US10507201B2

公开(公告)日：2019-12-17

申请号：US16289612

申请日：2019-02-28

Applicant: NOVARTIS AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Pascal Furet ,  Diana Graus Porta ,  Carolina Haefliger ,  Bo Han ,  Thomas Knöpfel ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Masato Murakami ,  Pierre Nimsgern ,  Michael Palmer ,  Dale Porter ,  Sebastien Ripoche ,  Can Wang ,  Youzhen Wang ,  Andreas Weiss ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/475 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/55 ,  A61P35/00 ,  A61K31/4375

Abstract: The present invention relates to therapeutic uses of compounds of formula (I) or a pharmaceutically acceptable salt thereof

公开(公告)号：US10130629B2

公开(公告)日：2018-11-20

申请号：US15561209

申请日：2016-03-23

Applicant: Novartis AG

Inventor： Nicole Buschmann ,  Robin Alec Fairhurst ,  Jorge Garcia Fortanet ,  Pascal Furet ,  Diana Graus Porta ,  Nafeeza Hafeez ,  Bo Han ,  Thomas Knoepfel ,  Matthew J. LaMarche ,  Catherine Leblanc ,  Lv Liao ,  Robert Mah ,  Dale Porter ,  Can Wang ,  Markus Wartmann ,  Jing Xiong ,  Xianglin Zhao

IPC: A61K31/496 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5377

Abstract: A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

公开(公告)号：US20170304313A1

公开(公告)日：2017-10-26

申请号：US15517035

申请日：2015-10-02

Applicant: Novartis AG

Inventor： Dale Porter ,  Nafeeza Hafeez

IPC: A61K31/55 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06

CPC classification number: A61K31/55 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00

Abstract: This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or preventing a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

公开(公告)号：US10765680B2

公开(公告)日：2020-09-08

申请号：US16475389

申请日：2018-01-05

Applicant: LES LABORATOIRES SERVIER ,  NOVARTIS AG

Inventor： Dale Porter ,  Ensar Halilovic ,  Maïa Chanrion ,  Ana Leticia Maragno ,  Olivier Geneste ,  Delphine Merino ,  James Whittle ,  François Vaillant ,  Jane Visvader ,  Geoffrey Lindeman ,  Guillaume Lessene ,  Elisabetta Marangoni

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/337 ,  A61P35/00

Abstract: A combination comprising a MCL-1 inhibitor and a taxane compound, and compositions and uses thereof.

公开(公告)号：US09446043B2

公开(公告)日：2016-09-20

申请号：US14647939

申请日：2013-11-26

Applicant: Novartis AG

Inventor： Dale Porter ,  Caroline Emery ,  Lujian Tan ,  Padmaja Yerramilli-Rao

IPC: A61K31/517 ,  A61K31/496 ,  A61K31/4184 ,  A61K31/4025 ,  A61K31/404 ,  A61K45/06 ,  A61K31/506

CPC classification number: A61K31/517 ,  A61K31/4025 ,  A61K31/404 ,  A61K31/4184 ,  A61K31/496 ,  A61K31/506 ,  A61K45/06 ,  A61K2300/00

Abstract: A pharmaceutical combination comprising (a) a protein kinase C (PKC) inhibitor compound, or a pharmaceutically acceptable salt thereof, and (b) at least one mitogen activated protein kinase (MEK) inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

Abstract translation: 一种药物组合，其包含（a）蛋白激酶C（PKC）抑制剂化合物或其药学上可接受的盐，和（b）至少一种丝裂原活化蛋白激酶（MEK）抑制剂或其药学上可接受的盐，以及任选的药学上可接受的盐 载体，用于同时，分开或顺次施用; 这种组合在增殖性疾病治疗中的应用; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。